Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers.
Barrett AM, Britton ZT, Carrasco RA, Breen S, Broggi MAS, Hatke AL, Clark B, Yang C, Phipps S, Ortiz L, Janocha B, Zanvit P, Giraldo NA, Martin PL, Lapointe JM, Harder N, Cornish GH, Attili BNNR, Mazor Y, Damschroder M, Cobbold M, Moody G, Bosco EE.
Barrett AM, et al. Among authors: britton zt.
Clin Cancer Res. 2024 Dec 2;30(23):5413-5429. doi: 10.1158/1078-0432.CCR-24-1853.
Clin Cancer Res. 2024.
PMID: 39321207
Free PMC article.